DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with deadly brain tumors: combination drug trial launches
Disease control Recruiting nowThis phase 2 trial is testing whether combining the drug ONC201 with other treatments (like paxalisib or a cancer-killing virus called DNX-2401) can help children and young adults with diffuse midline gliomas, a rare and aggressive brain cancer. The study enrolls 360 participants…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for young brain cancer patients: targeted drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests whether adding the drug olutasidenib to standard chemotherapy (temozolomide) can help children and young adults with a specific type of brain cancer (IDH1-mutant high-grade glioma) live longer. About 60 participants will receive the combination as maintenance the…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: Rigel Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for kids with aggressive brain cancer: targeted drug combo trial launches
Disease control Recruiting nowThis study tests whether adding two different drug combinations after radiation can help children and young adults (up to age 21) with high-grade gliomas, including DIPG, live longer. One group receives ribociclib plus everolimus; another gets ribociclib plus temozolomide. The go…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for deadly brain tumors: Drug-Radiation combo trial opens
Disease control Recruiting nowThis study tests whether adding the drug VRT106 to standard radiation therapy can help control a rare, fast-growing brain tumor called diffuse midline glioma (including DIPG) in adults. About 10 participants aged 18 to 75 will receive the combination treatment. The main goal is t…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Engineered immune cells delivered directly to the brain show promise for kids with deadly tumors
Disease control Recruiting nowThis early-stage trial tests a new treatment for children and young adults up to age 21 with certain brain tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a pro…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental vaccine combo takes on childhood brain cancer
Disease control Recruiting nowThis early-phase trial is testing a new vaccine (rHSC-DIPGVax) made from pieces of tumor proteins, given together with two immunotherapy drugs (balstilimab and zalifrelimab), in children with DIPG or diffuse midline glioma. The goal is to see if the combination is safe and tolera…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for kids with DIPG: major trial compares two treatments
Disease control Recruiting nowThis phase 3 trial tests whether the drug ONC201 works better than everolimus for children and adults with DIPG, a rare and aggressive brain tumor. About 433 participants will receive one of the two drugs, and can switch if their disease gets worse. The goal is to see which drug …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Sound waves open brain barrier to attack deadly childhood tumors
Disease control Recruiting nowThis early study tests whether focused ultrasound can safely open the blood-brain barrier in children with progressive diffuse midline glioma (DMG), a rare and aggressive brain tumor. Ten children aged 4–21 will receive oral etoposide chemotherapy after ultrasound treatment to al…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New pill shows promise in early brain tumor trial
Disease control Recruiting nowThis early-stage study tests an oral drug called ONC206 in adults with brain tumors that have come back. The main goal is to find the safest dose and check for side effects. About 102 participants will take the drug once or several times a week.
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Could two weeks of radiation be as good as six for this brain cancer?
Symptom relief Recruiting nowThis study is for people with a rare and aggressive brain tumor called diffuse midline glioma. Instead of the usual six weeks of daily radiation, researchers are testing a shorter course of just two weeks. The goal is to see if the shorter treatment works just as well at controll…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Brain tumor DNA test could match kids to smarter treatments
Knowledge-focused Recruiting nowThis study uses genetic testing of brain tumors from children, adolescents, and young adults (ages 1 to 39) with newly diagnosed high-grade glioma, including DIPG. The goal is to identify specific genetic changes in each tumor and then see if patients can join a treatment trial t…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Sponsor: Nationwide Children's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New brain tumor labels could guide better treatments
Knowledge-focused Recruiting nowThis study is collecting data from 1,650 people with various brain tumors to see if the updated 2021 WHO classification system helps doctors group patients more accurately and choose better treatments. Researchers will track responses to therapy, survival, and tumor features over…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Worldwide effort to crack the code of deadly childhood brain tumors
Knowledge-focused Recruiting nowThis study creates a central registry and tissue bank for people with DIPG or DMG, rare and aggressive brain tumors. Researchers will collect medical information, scans, and tumor samples from up to 1,500 patients of any age. The goal is to understand the biology of these tumors …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC